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Introduction {#jdi12003-sec-0001}
============

Hypertension is common in patients with type 2 diabetes and contributes to the progression of diabetic nephropathy and the incidence of cardiovascular disease[1](#jdi12003-bib-0001){ref-type="ref"}. Several studies have suggested that the use of blockers of the renin--angiotensin system (RAS) slows the progression of diabetic nephropathy[2](#jdi12003-bib-0002 jdi12003-bib-0003){ref-type="ref"}, and they are recommended as the primary antihypertensive drugs[4](#jdi12003-bib-0004){ref-type="ref"}. However, the use of only one type of antihypertensive agents is inadequate to achieve the target blood pressure level, and might not be sufficient to reduce albuminuria or proteinuria.

The most frequently used calcium channel blocker (CCB) in Japan is amlodipine. Amlodipine belongs to the L‐type calcium channel blockers, and has a potent blood pressure lowering effect and few adverse effects. The CCB‐induced drop in blood pressure often stimulates sympathetic nerve activity, leading to tachycardia.

Cilnidipine is a CCB that inhibits not only the L‐type calcium channel, but also the N‐type calcium channel. As the N‐type calcium channel is abundantly expressed in peripheral sympathetic nerve endings[5](#jdi12003-bib-0005){ref-type="ref"}, cilnidipine reduces excessive release of catecholamine and suppresses reflective tachycardia compared with amlodipine in hypertensive patients[6](#jdi12003-bib-0006 jdi12003-bib-0007){ref-type="ref"}. In addition, a recent study showed that the L‐type CCB inhibitors dilate the afferent, but not the efferent, arteries of glomeruli; whereas cilnidipine dilates both the afferent and efferent arteries, suggesting that N‐type calcium channel inhibition seems to attenuate glomerular hypertension and prevent proteinuria[8](#jdi12003-bib-0008){ref-type="ref"}. Indeed, cilnidipine was shown to have a superior effect to amlodipine in preventing the progression of proteinuria in hypertensive patients[8](#jdi12003-bib-0008 jdi12003-bib-0009){ref-type="ref"}.

Azelnidipine is also a unique long‐acting L‐type calcium channel inhibitor that decreases heart rate and proteinuria by suppressing sympathetic nerve activity[10](#jdi12003-bib-0010 jdi12003-bib-0011){ref-type="ref"}. Clinical studies also confirmed that azelnidipine significantly reduced heart rate and proteinuria in hypertensive patients[12](#jdi12003-bib-0012 jdi12003-bib-0013){ref-type="ref"}.

Thus, among the available CCBs, both cilnidipine and azelnidipine seem to have better renoprotective effects; however, there are no comparative data on the renoprotective effects of cilnidipine and azelnidipine in patients with type 2 diabetes.

Methods {#jdi12003-sec-0002}
=======

Patients {#jdi12003-sec-0003}
--------

All patients with type 2 diabetes mellitus who visited Juntendo University Hospital (Tokyo, Japan) between January 2009 and November 2010 were asked to participate. The inclusion criteria were patients with type 2 diabetes mellitus and hypertension treated with amlodipine 5 mg once daily for at least 12 weeks. Patients with severe renal or hepatic disease, overt cardiovascular disease, malignancy and macroalbuminuria (defined as ≥300 mg/g creatinine by examination of a spot urine sample at a screening point) were excluded. The hospital ethics committee approved the study protocol and informed consent was obtained from each patient.

Study Design {#jdi12003-sec-0004}
------------

After completion of run in period (amlodipine 5 mg once‐daily), blood pressure was monitored continuously over a 24‐h time period using an ambulatory blood pressure monitoring (ABPM) device (A&D Company, Tokyo, Japan), followed by collection of fasting blood samples. Then, the participants were randomized into one of two treatment groups; the 10 mg cilnidipine group and the 16 mg azelnidipine group, once daily in the morning instead of amlodipine. After 16 weeks of cilnidipine or azelnidipine treatment, blood pressure was again monitored with ABPM and fasting blood samples were collected. Then, the patients on cilnidipine were switched to azelnidipine, and the patients on azelnidipine were switched to cilnidipine, and each group continued the treatment for 16 weeks, after which another ABPM was carried out followed by fasting blood sampling. During the study period, except for CCBs, no changes were made to the types and doses of other drugs used before the study.

Biochemical Tests {#jdi12003-sec-0005}
-----------------

Blood samples were obtained between 08.00 h and 10.00 h after overnight fast. The value of glycated hemoglobin (HbA~1c~;%; Tosho, Tokyo, Japan) was estimated as a National Glycohemoglobin Standardization Program (NGSP) equivalent value (%)[14](#jdi12003-bib-0014){ref-type="ref"}. Urinary albumin excretion:creatinine ratio (UACR; DENKA SEIKE CO. Ltd. Tokyo, Japan; KAINOS Laboratories, Inc, Tokyo, Japan) was measured by latex agglutination assay using a spot urine sample.

Blood Pressure Evaluation {#jdi12003-sec-0006}
-------------------------

The ABPM device was used for blood pressure measurement, as reported previously by our group[15](#jdi12003-bib-0015 jdi12003-bib-0016){ref-type="ref"}.

Statistical Analysis {#jdi12003-sec-0007}
--------------------

Differences between groups were examined for statistical significance using the two‐tailed paired Student\'s *t*‐test or Wilcoxon signed‐rank test. A *P*‐value less than 0.05 denoted the presence of a statistically significant difference.

Results {#jdi12003-sec-0008}
=======

A total of 23 diabetic patients with hypertension were randomly assigned to the first cilnidipine group (*n* = 12) and the first azelnidipine group (*n* = 11). Of these, 19 patients completed the first arm of the trial. Four patients dropped out (one lost to follow up, one refusal to use ABPM, one acute myocardial infarction, one traffic accident). No serious adverse effects were observed in all study patients including the four drop‐out cases. The demographic characteristics and mean baseline data are shown in Tables [1](#jdi12003-tbl-0001){ref-type="table-wrap"} and [2](#jdi12003-tbl-0002){ref-type="table-wrap"}.

###### Baseline characteristics of study participants

  *n*                                                                        19
  -------------------------------------------------------------------------- ------------
  Age (years)[a](#jdi12003-note-0001){ref-type="fn"}                         63.7 ± 6.9
  Sex (male/female)                                                          13/6
  Bodyweight (kg)[a](#jdi12003-note-0001){ref-type="fn"}                     68.3 ± 8.7
  Mean duration of diabetes (years)[a](#jdi12003-note-0001){ref-type="fn"}   14.7 ± 3.9
  Current smokers (*n)*                                                      3
  Medications                                                                
  Other antihypertensive medications                                         
  Angiotensin II type I receptor blockers (*n*)                              12
  Others (*n*)                                                               4
  Glucose lowering agents                                                    
  Sulfonylurea (*n*)                                                         10
  Glinide (*n*)                                                              3
  α‐Glucosidase (*n*)                                                        6
  Thiazolinedione (*n*)                                                      4
  Metformin (*n*)                                                            8
  Statins (*n*)                                                              7
  Anti‐platelet agents (*n*)                                                 7

Data are mean ± standard deviation or number of participants.
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###### Blood pressure (mmHg) recorded by 24‐h ambulatory blood pressure monitoring and biochemical measurements during each treatment

  Variable                          Baseline(amlodipine)   Cilnidipine    Azelnidipine   *P*‐value[a](#jdi12003-note-0003){ref-type="fn"}
  --------------------------------- ---------------------- -------------- -------------- --------------------------------------------------
  24‐h data                                                                              
  Systolic BP (mmHg)                131.4 ± 9.1            134.4 ± 14.0   134.8 ± 13.0   NS
  Diastolic BP (mmHg)               77.6 ± 5.4             78.6 ± 6.7     78.0 ± 7.1     NS
  Heart rate (b.p.m.)               73.6 ± 10.2            70.3 ± 8.8     69.0 ± 8.2     NS
  Daytime                                                                                
  Systolic BP (mmHg)                136.2 ± 9.5            138.6 ± 14.0   138.3 ± 11.2   NS
  Diastolic BP (mmHg)               80.5 ± 6.2             81.3 ± 6.7     81.1 ± 7.3     NS
  Heart rate (b.p.m.)               77.1 ± 10.6            74.2 ± 9.5     72.1 ± 9.4     NS
  Nighttime                                                                              
  Systolic BP (mmHg)                119.8 ± 12.1           124.8 ± 17.9   125.7 ± 18.9   NS
  Diastolic BP (mmHg)               70.0 ± 6.3             72.1 ± 8.7     71.2 ± 9.4     NS
  Heart rate (b.p.m.)               64.6 ± 9.0             63.5 ± 9.2     62.4 ± 10.3    NS
  Body mass index (kg/m^2^)         25.5 ± 4.1             25.6 ± 4.2     25.8 ± 4.4     NS
  Clinic systolic BP (mmHg)         128.1 ± 10.0           129.8 ± 11.3   129.3 ± 18.3   NS
  Clinic diastolic BP (mmHg)        71.7 ± 10.0            72.1 ± 9.7     72.0 ± 11.7    NS
  HbA~1c~ (%) (NGSP)                7.26 ± 0.99            7.22 ± 1.21    7.26 ± 1.02    NS
  High‐density lipoprotein (mmol)   1.39 ± 0.32            1.39 ± 0.35    1.40 ± 0.38    NS
  Low‐density lipoprotein (mmol)    2.99 ± 0.66            3.02 ± 0.72    3.03 ± 0.77    NS
  Triglyceride (mmol)               1.56 ± 0.72            1.51 ± 0.70    1.45 ± 0.62    NS
  Cre (μmmol)                       71.8 ± 14.3            74.5 ± 17.0    76.4 ± 18.7    NS
  Uric acid (mmol)                  0.34 ± 0.08            0.33 ± 0.8     0.35 ± 0.9     \<0.05
  Log UACR (mg/mmol)                9.47 ± 10.9            8.60 ± 9.9     12.3 ± 17.3    \<0.05

Data are mean ± standard deviation or number of participants.

Comparison between cilnidipine and azelnidipine groups by two‐tailed Student\'s *t*‐test or Wilcoxon signed‐rank test. Night‐time was defined as the period between the time when the patients retired to their beds and the time when they woke up the next morning. BP, blood pressure; Cre, creatinine; HbA~1c~, glycated hemoglobin; NPSG, National Glycohemoglobin Standardization Program; NS, not significant; UACR, Urinary albumin excretion/creatinine ratio. \[Correction added on 7 Feb 2013, after first online publication: The cilnidipine and azelnidipine values for uric acid were changed to 0.33 ± 0.08 and 0.35 ± 0.09 respectively.\]
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Table [2](#jdi12003-tbl-0002){ref-type="table-wrap"} shows the systolic and diastolic blood pressures analyzed by 24‐h ABPM. There were no significant differences in these parameters between cilnidipine and azelnidipine. The heart rate was also similar in both groups. In contrast, compared with the cilnidipine treatment, azelnidipine significantly reduced UACR and uric acid levels. Other metabolic and renal function tests were comparable between the two treatment groups.

Discussion {#jdi12003-sec-0009}
==========

In the present study, heart rate tended to decrease under both cilnidipine and azelnidipine treatments, compared with baseline (amlodipine), suggesting similar beneficial effects on the sympathetic nerve activity. Nevertheless, we found that cilnidipine reduced UACR more than azelnidipine despite the similar blood pressure level. The exact reason for the better effect of cilnidipine on albuminuria relative to azelnidipine is not clear. However, it is possible that cilnidipine reduced proteinuria through the inhibition of N‐type calcium channel in the podocytes[17](#jdi12003-bib-0017){ref-type="ref"}. Podocytes play a pivotal role in glomerular filtration barrier[18](#jdi12003-bib-0018){ref-type="ref"}, and are known to express N‐type calcium channel[17](#jdi12003-bib-0017){ref-type="ref"}. Inhibition of this channel in podocytes by cilnidipine might prevent podocyte injury, leading to protection of glomerular filtration[17](#jdi12003-bib-0017){ref-type="ref"}.

In the present study, cilnidipine significantly reduced uric acid compared with azelnidipine, but the mechanism of this action is unknown at this stage. However, it was shown that skeletal muscles in patients with hypertension might be an important source of uric acid, because activation of muscle‐type adenosine monophosphate deaminase by hypoxia increased hypoxathine, the precursor of uric acid[19](#jdi12003-bib-0019){ref-type="ref"}. Cilnidipine was shown to decrease these productions of uric acid precursor in skeletal muscles[20](#jdi12003-bib-0020){ref-type="ref"}. Epidemiological studies suggest that uric acid concentration correlates with urinary albumin excretion and subclinical atherosclerosis in patients with type 2 diabetes[21](#jdi12003-bib-0021){ref-type="ref"}, and lowering uric acid could slow the progression of renal disease in non‐diabetic patients[22](#jdi12003-bib-0022){ref-type="ref"}. Thus, the reduction of uric acid by cilnidipine seems to be beneficial for renoprotection and prevention of atherosclerosis.

The limitation of the present pilot study is the small number of patients studied over a short period of time, although the crossover design is statistically efficient and thus requires fewer participants than non‐crossover designs. In addition, we could not set up a washout period for reasons related to ethical standards and clinical management of patients[15](#jdi12003-bib-0015 jdi12003-bib-0021 jdi12003-bib-0023){ref-type="ref"}. However, further studies that are set up with a washout period or a third period with amlodipine treatment between cilnidipine and azelnidipine treatments, considering ethical problems, are required to clarify the differential effects more clearly in the future. Although we measured UACR only once using a spot urine sample, the accuracy will improve by measuring UCAR more than twice or albuminuria using urine collection for a day.

In conclusion, our data suggest that cilnidipine can be considered a unique CCB that can prevent the progression of diabetic nephropathy in type 2 diabetic patients with hypertension.
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